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Abstract Nasopharyngeal carcinoma (NPC), a distinct type
of head and neck cancer, is prevalent in Southeast Asia and
southern China. Ethnic background and environmental factors
contribute to the development of NPC, further complicating
its pathogenesis. An increasing body of evidence indicates
that microRNAs (miRNAs) play an important role in the
development and progression of NPC, in particular, 32
miRNAs are involved in NPC tumorigenesis, progression,
and metastasis. The causal involvement of miRNAs in NPC
and their possible use as biomarkers have been extensively
studied with promising results, demonstrating the diagnostic
and therapeutic potential of miRNAs in NPC. In this review,
we summarize the role of all the known miRNAs involved in
the signaling pathway implicated in NPC.
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Introduction
Nasopharyngeal carcinoma (NPC) is endemic in southern
China and Southeast Asia with an annual incidence of 15–
50 cases per 100,000 [1]. Both ethnic background and
environmental factors contribute to the risk of NPC develop-
ment. The Chinese population emigrating to Southeast Asia or
North America is considered to be at high risk. In contrast, the
incidence of NPC is much lower in the Chinese individuals
born in North America [2, 3]. According to global cancer
statistics reported by the International Agency for Research
on Cancer, over 84,000 new NPC cases occur annually,
among which 80 % are located in Asia and 5 % in Europe.
NPC is characterized by poorly or undifferentiated carcinoma.
It differs from non-nasopharyngeal head and neck squamous
cell carcinomas in several ways including its association with
the Epstein–Barr virus (EBV) and a great propensity for
distant metastases [4]. Advances in radiotherapy and compre-
hensive chemotherapy strategies have greatly improved out-
comes in the patients with primary NPC; the 5-year survival
rate increases from 50 % in the 1980s to 70 % in the 1990s
[5, 6]. However, 15–58 % of NPC patients experience
recurrence of the disease and have to undergo re-treatment [7, 8].
MicroRNAs (miRNAs or miRs) are endogenous, small,
non-coding single-stranded RNAs of ∼22 nucleotides in
length, of which negative regulators of gene expression are
small non-coding RNAs that typically inhibit the transla-
tion and reduce the stability of messenger RNAs
(mRNAs). Thereby, they are involved in cellular processes
such as inflammation, cell-cycle regulation, stress re-
sponse, differentiation, apoptosis, and migration [9]. The
annotation of miRNAs genomic positions indicates that
most miRNA-coding genes are located in the introns of
protein-coding genes, and the introns or exons of non-
coding genes [10]. miRNAs can be organized as individual
genes or localized as clusters representing miRNA fami-
lies, which are commonly related in their sequence and
function. miRNAs are mainly transcribed by RNA poly-
merase II (RNA pol II) from their own promoter or the
promoter of the host gene in which they reside. The RNA
pol II synthesizes large miRNA precursors called primary-
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miRNAs (pri-miRNAs) [11]. The canonical miRNA bio-
genesis pathway consists of two main processing steps that
occur in the nucleus and the cytoplasm. pri-miRNAs are
first processed into the nucleus and then cleaved into a 60–
70 nt double-helix hairpin structure (called precursor
miRNA or pre-miRNA) by the RNase III Drosha and its
cofactor DGCR8 [12]. Exportin 5 mediates the transfer of
the pre-miRNA into the cytoplasm [13], where the second
cropping process (dicing) takes place. The pre-miRNA is
first processed by the RNase III Dicer, in concert with TAR
RNA binding protein or protein activator of the interferon-
induced protein kinase cofactors, into a 22 nt dsRNA with
two-nucleotide 3′-overhangs called miRNA/miRNA* du-
plex. It is finally unwound by a cytoplasmic helicase [14].
The mature miRNA guide is generally selected according
to its thermodynamic properties, while the complementary
passenger strand is usually subject to degradation. It was
formerly thought that the miRNA strand is preferentially
degraded; however, more recent evidence suggests that it
does not simply represent a non-functional byproduct of
miRNA biogenesis but can be selected as the functional
strand to play significant biological roles [15].
The miRNA strand with the less stable 5′ end (guide
strand) is preferentially selected and incorporated in the
RNA-induced Silencing Complex. The mature miRNA
regulates gene expression at the posttranscriptional level
by binding through partial complementarity to target
mRNAs [generally the 3′-untranslated regions (UTR)],
which results in mRNA degradation or translation inhibi-
tion [16]. Indeed, miRNAs mainly recognize complemen-
tary sequences in the 3′-UTRs of their target mRNAs;
however, recent studies have reported that miRNAs can
also bind to the 5′-UTR or the open reading frame.
Surprisingly, they can also upregulate translation under
conditions of growth arrest [17, 18]. Moreover,
miRNAs, as well as dsRNAs, are known to bind promoter
regions at the genomic level and induce gene expression
by returning to the nucleus or a hexanucleotide terminal
motif-mediated transfer [19, 20].
Genetic variants of the miRNA biogenesis pathway are
associated with the risk and/or survival in various malignan-
cies such as bladder, ovarian, prostate, and breast cancer
[21–24]. miRNAs can also be secreted in the surrounding
region or the biological fluids where they are protected in
liposomal-like particles and act on other cell types. Indeed,
increasing evidences reveal that circulating miRNAs are as-
sociated with microvesicles—small exosomes/vesicles of
endocytic origin, which are released by normal healthy or
damaged cell types. In the present review, we summarize
miRNAs in the carcinogenesis and metastasis of NPC, their
potential as therapeutic targets and diagnostic markers, and
their mediating signal pathway. This provides a novel clue for
further investigating NPC.
miRNAs are involved in multiple stages of NPC
tumorigenesis
miRNA expression in NPC
Since the discovery of miRNAs and their involvement in
chronic lymphocytic leukemia [25], the role of miRNA dys-
regulation in NPC pathogenesis has been studied extensively
[26]. miRNAs may function as oncogenes or tumor suppres-
sors in the malignant progression of different tumor types.
Profiling analysis indicated that a large number of miRNAs
are either down- or upregulated in NPC tissues. Table 1 enlists
a number of miRNAs involved in NPC, as supported by
validated experimental data.
miRNA functions as a tumor suppressor to regulate NPC
Generally, cancer develops sophisticated networks of multiple
signaling pathways, which contribute to their ability to prog-
ress, in some cases, and to evade treatment. Gain-of-function
and loss-of-function experiments, in combination with target
prediction analyses, have demonstrated that miRNAs can
influence multiple steps of tumorigenesis [27]. miRNAs that
function as tumor suppressors are often downregulated in
NPC tissues. Since these miRNAs are negative regulators of
protein-coding genes, the downregulation of miRNAs is ex-
pected to cause an upregulation of their target genes and
subsequent alterations of the associated cellular pathways in
NPC (Fig. 1). Among the tumor suppressor microRNAs in-
volved in NPC, the miR-9, miR-26, miR-29, miR-200 family,
and the Let-7 family are the most common.
miR-9 appears to be one of the most important players in
NPC biology; while it is commonly downregulated in NPC, it
is known to regulate proliferation, epithelial–mesenchymal
transition (EMT), invasion, metastasis, apoptosis, and angio-
genesis in other cancers (Fig. 1) [28, 29]. Mechanistically,
miR-9 can directly bind to the 3′-UTR of CXCR4 to down-
regulate its expression. CXCR4 downregulation inhibits cell
growth, migration, and invasion, whereas its overexpression
rescues the suppressive effect of miR-9 [30]. In addition, miR-
9 can modulate the expression of interferon-induced genes
and major histocompatibility complex class I molecules in
human cancer cells, indicating a novel role of miR-9 in linking
inflammation and cancer [31]. Ectopic expression of miR-9
dramatically inhibits the proliferative, migratory, and invasive
capabilities of NPC cells both in vitro and in vivo. Low
plasma levels of miR-9 are significantly correlated with in-
creased lymphatic invasion and advanced TNM stage.
Furthermore, these levels are significantly higher in post-
treatment samples than in pre-treatment samples [32]. miR-
26a functions to suppress growth in NPC; however, miR-26a
is commonly downregulated in NPC specimens and cell lines;
its ectopic expression dramatically suppresses cell
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proliferation and colony formation by inducing G1 cell-cycle
arrest. In addition, miR-26a strongly reduces the expression of
the EZH2 (Zeste homolog 2) oncogene in NPC cells (Fig. 1)
[33]. Mechanistically, miR-26a suppresses the expression of
c-Myc, cyclins D3 and E2, and the cyclin-dependent kinases
(CDK), CDK4 and CDK6, enhances the expression of the
CDK inhibitors p14(ARF) and p21(CIP1) in an EZH2-
dependent manner. The antimetastatic functions of miR-26a
are primarily mediated by repressing EZH2 expression [34].
miR-29c is also downregulated in NPC; its ectopic expression
inhibits NPC cell migration and invasion in vitro and
suppresses the formation of lung metastases in vivo. Studies
using luciferase reporter assays have confirmed that T cell
lymphoma invasion and metastasis 1 (TIAM1) is a miR-29c
target gene [35]. Reduced expression of miR-29c is positively
correlated with therapeutic resistance in NPC patients.
Mechanistically, miR-29c substantially enhances the sensitiv-
ity of NPC cells to ionizing radiation (IR) and cisplatin treat-
ment through the repression of antiapoptotic factors, Mcl-1
and Bcl-2 [36]. Moreover, miR-98 is also found to be
underexpressed in relapsed NPC patient samples. Using
luciferase-based assays, miR-98 has been validated as a bona
Table 1 List of miRNAs involved in NPC, their validated targets, and biological functions
miRNAs Validated target(s) Main biological function(s)
Tumor suppressors
miR-1 PTMA Induces carcinoma cell apoptosis
miRNA let-7 c-Myc, EZH2 Inhibits cell proliferation and induces cell apoptosis
miR-9 CXCR4 Regulates proliferation, EMT, invasion, metastasis, apoptosis, and tumor
angiogenesis
miR-26a EZH2, c-Myc Suppresses cell proliferation and colony formation
miR-29c TIAM1 Inhibits cell migration and invasion
miR-98 EZH2 Inhibits relapse
miR-124 Foxq1 Inhibits cell growth, migration, and invasion
miR-138 CCND1 Suppresses cell proliferation and colony formation
miR-184 BCL2, c-Myc Suppresses cell proliferation
miR-200 ZEB2, CTNNB1, Notch1 Regulates EMT, migration, and invasion
miR-204 Stat-3, CDC42 Regulates invasion
miR-216b PKCá, K-Ras Suppresses proliferation and invasion
miR-375 MTDH Suppresses relapse
miR-451 MIF Regulates NPC cell growth and invasion
Onco-miRNAs
miR-10b MMP-9 Promotes mobility and invasion
miR-18a Dicer1, c-Jun, c-Myc, Lymph node metastasis
miR-18b CTGF Promotes cell growth
miR-21 BCL2 Promotes migration and proliferation
miR-30a E-cadherin Increases the capability of metastasis and invasion
miR-93 TGFâR2 Promotes cell proliferation, invasion, and metastasis
miR-141 BRD3, PTEN, SPLUNC1 Promotes cell growth, migration, and invasion
miR-144 PTEN Promotes migration and invasion
miR-149 E-cadherin Promotes mobility and invasion
miR-155 JMJD1A, BACH1 Stimulates cell proliferation, colony formation, cell migration, and invasion
miR-205 PTEN Attenuates cell apoptosis post-irradiation
miR-214 LTF, Bim Promotes NPC cell proliferation, invasion, and metastasis
miR-378 TOB2 Promotes cell proliferation, colony formation, migration, and invasion
miR-421 FOXO4 Induces cell growth and apoptosis resistance
miR-663 p21 Promotes cellular G1/S transition
PTMA prothymosin alpha or ProTalpha, IFN interferon,MHCmajor histocompatibility complex,CXCR4 chemokine (C-X-Cmotif) receptor 4,CCND1
cyclin D1, ZEB E-box binding homeobox, CTNNB1 catenin (cadherin-associated protein), beta 1, CDC42 cell division cycle 42, PKC protein kinase C,
MIFmacrophage migration inhibitory factor,MMP-9matrix metalloproteinase-9,CTGF connective tissue growth factor, TGFβR2 transforming growth
factor-β receptor II, BRD3 bromodomain containing 3,PTEN phosphatase and tensin homolog, SPLUNC1 short palate, lung, and nasal epithelium clone
1, JMJD1A, BACH1 BTB and CNC homology 1, LTF lactotransferrin, TOB2 transducer of ERBB2, FOXO4 forkhead box O 4
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fide regulator of the expression of EZH2, which is associated
with a higher risk of relapse in NPC patients [37].
miR-200 family is often downregulated in NPC. The over-
expression of miR-200a inhibits the growth, migration, and
invasion of C666-1 cells (Fig. 1), whereas its knock-down
stimulates these processes in CNE-1 cells. It is speculated that
E-box binding homeobox 2(ZEB2), catenin (cadherin-associ-
ated protein), and beta 1(CTNNB1) are the functional down-
stream targets of miR-200a. The knock-down of ZEB2 solely
impedes NPC cell migration and invasion, whereas CTNNB1
suppression inhibits NPC cell growth. These suggest that the
inhibitory effects of miR-200a onNPC cell growth, migration,
and invasion are mediated by distinct targets and pathways
[38]. miR-200a also regulates EMT as well as stem cell-like
transition in NPC cells (Fig. 1). Stable knockdown of miR-
200a promotes the transition of epithelium-like CNE-1 cells to
the mesenchymal phenotype. Similarly, stable overexpression
of miR-200a transfers the mesenchyme-like C666-1 cells to
the epithelial state along with a significant reduction of their
stem cell-like features. Mechanistically, miR-200a controls
EMT by targeting ZEB2, and it also regulates the stem cell-
like transition differentially and specifically throughβ-catenin
signaling [39]. EBV-encoded EB nuclear antigen 1 (EBNA1)
inhibits the expression of miR-200a and miR-200b, which
results in the upregulation of target genes expression and zinc
finger E-box binding homeobox 1 (ZEB1) and ZEB2 [40].
miR-200b is significantly downregulated in the NPC tissues
and cell lines. Gain-of-function and loss-of-function studies
have demonstrated that miR-200b suppresses NPC cell
growth, migration, and invasion in vitro (Fig. 1).
Importantly, the overexpression of miR-200b effectively re-
presses tumor growth in nude mouse models. Furthermore,
integrated analysis has identified Notch1 as a direct and func-
tional target of miR-200b. Overexpression of Notch1 reverses
the inhibitory effect of miR-200b on NPC cell growth and
invasion [41].
The Let-7 family is one of the best known miRNA families
in cancer biology. It regulates numerous oncogenes like RAS,
MYC, and high-mobility group AT-hook 2 (HMGA2) [42,
43]. NPC cells exhibit reduced levels of miRNA Let-7 (Let-7-
a, Let-7-b, Let-7-d, Let-7-e, Let-7-g, and Let-7-i). Ectopic
expression of the Let-7 family inhibits NPC cell proliferation
by downregulating c-Myc expression. Demethylation treat-
ment of NPC cells causes the activation of Let-7 expression
in poorly differentiated NPC cells [44]. EZH2 is a direct target
of Let-7a, and the in vitro inhibition of EZH2 by Let-7a and/or
EZH2 siRNA attenuates NPC cell growth, inhibits cell prolif-
eration, and induces cell apoptosis, respectively (Fig. 1) [45].
Besides the afore-mentioned microRNAs, miR-204, miR-
216b, miR-143, miR-375, miR-451, miR-375, miR-1, miR-
124, miR-138, and miR-184 are known to be downregulated
in NPC cells and tissues (Fig. 1). Reduced expression of miR-
204 is strongly associated with a more aggressive and poor
prognostic phenotype of NPC. EBV-encoded latent mem-
brane protein 1 (LMP-1) suppresses miR-204 expression by
activating Stat-3 and enhances cell division cycle 42 (CDC42)
Fig. 1 Schematic illustration of
microRNAs (miRNA) involved
in nasopharyngeal carcinoma






invasion. Some miRNAs are
associated with clinical prognosis.
Plus sign upregulated miRNA;
minus sign downregulated
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activity to facilitate the invasion of NPC [46]. Similarly,
decreasedmiR-216b expression is directly related to advanced
clinical stage and lymph nodemetastasis in NPC. Both in vitro
and in vivo assays have revealed that miR-216b attenuates
NPC cell proliferation, invasion (Fig. 1), and tumor growth in
nude mice. miR-216b exerts its tumor suppressor function by
inhibiting the KRAS-related (protein kinase B) AKT and
extracellular signal-regulated kinase (ERK) pathways [47].
Additionally, the miR-216b-mediated downregulation of pro-
tein kinase C α (PKCα) suppresses the proliferation and
invasion ability of CNE2 cells; moreover, overexpressed
PKCα can partially reverse the inhibitory effect of miR-
216b on cell proliferation [48]. Patients with low miR-451
expression have poor overall and disease-free survival com-
pared with those with high miR-451 expression. Macrophage
migration inhibitory factor, a direct target of miR-451, regu-
lates NPC cell growth and invasion [49]. miR-143 plays a role
in modulating the invasiveness and metastasis of NPC; its
overexpression causes a significant reduction of the adhesion
ability [50]. Studies using dual-luciferase reporter assays
showed that miR-143 directly binds to the 3′-UTR of GLI3.
In addition, results from qRT-PCR and Western blot analysis
demonstrated that the expression of miR-143 is negatively
correlated to GLI3 and suppresses the migration of 5–8 F cells
[51]. In the NPC samples, miR-375 expression is significantly
reduced, while metadherin (MTDH) is significantly increased.
NPC patients with highMTDH experience significantly lower
survival, as well as higher distant relapse rates. Luciferase
assays have also corroborated MTDH as a target of miR-375
[52]. miR-1 can induce NPC cell apoptosis by directly
targeting the prothymosin alpha gene, in which siRNA and
miR-1 accelerate the apoptotic process in cells treated with
apoptosis inducers [53]. miR-124 is also commonly downreg-
ulated in NPC specimens and cell lines, and its expression is
inversely correlated with clinical stages. Foxq1 is a novel
direct target of miR-124, and its knockdown inhibits cell
growth, migration, and invasion (Fig. 1) [54]. miR-138 is
another downexpressed miRNA, and its ectopic expression
suppresses NPC cell proliferation and colony formation, and
also inhibits tumorigenesis in vivo (Fig. 1). Cyclin D1 is a
direct target of miR-138, and its mRNA levels are inversely
correlated with miR-138 expression [55]. miR-184, which is
modulated by programmed cell death 4 (PDCD4), directly
targets BCL2 and C-MYC and participates in PDCD4-
mediated suppression of cell proliferation and survival in
NPC [56].
Onco-miRNAs are involved in the regulation of NPC
In tumorigenesis of NPC, some miRNAs called onco-
miRNAs, function as oncogenes, for example, miR-18, miR-
214, miR-155, and miR-141. miR-18, a member of the onco-
genic miR-17-92 cluster, acts as an onco-miR in NPC
development (Fig. 1). Indeed, miR-18a is upregulated in
NPC samples and cell lines [57]. Clinical parameter studies
showed that miR-18a levels are correlated with advanced
stages of NPC, lymph node metastasis, EBV infection, and a
higher death rate. miR-18a negatively regulates Dicer1 by
binding to its 3′-UTR, resulting in global downregulation of
miR-200 family and miR-143 expression. The EMT marker
E-cadherin and oncogene K-Ras are aberrantly expressed after
miR-18a transduction, and these alterations are directly in-
duced by the downregulation of miR-200 family and miR-143
[58]. miR-18b directly suppresses the expression of connec-
tive tissue growth factor (CTGF) in NPC, and its downregu-
lation is significantly associated with NPC progression and
poor prognosis. In fresh clinical specimens, miR-18b was
widely overexpressed and inversely correlated with CTGF
expression [59]. miR-141 was also upregulated in the NPC
specimens. Both c-Myc knockdown and the re-expression of
the host defensive protein short palate, lung, and nasal epithe-
lium clone 1 (SPLUNC1) can downregulate miR-141. The
miR-141 inhibition, in turn, affects cell cycle, apoptosis,
growth, migration and invasion. Studies using luciferase re-
porter assays have confirmed that bromodomain containing
3(BRD3), ubiquitin-associated protein 1 (UBAP1), and PTEN
are the potential targets of miR-141 [60]. SPLUNC1 functions
at the very early stage of NPC carcinogenesis. It regulates
NPC cell proliferation, differentiation, and apoptosis through
miR-141, which in turn regulates the expression of PTEN and
p27. This signaling axis is negatively regulated by the EBV-
coded gene LMP1 [61]. Although miR-155 is upregulated in
the two EBV-negative NPC cell lines, Chinese nasopharyn-
geal carcinoma cell line 1 and nasopharyngeal carcinoma cell
line from Taiwan (TW03), EBV-encoded LMP1, and LMP2A
may further enhance miR-155 expression. Jumonji Domain
1A (JMJD1A) and BTB and CNC homology 1 (BACH1),
putative targets of miR-155, can be downregulated by miR-
155 mimics, while miR-155 inhibitor upregulates the expres-
sion of JMJD1A in the NPC cell lines. The downregulation of
JMJD1A is significantly correlated with the N stage of the
TNM classification, a lower 5-year survival rate, and a lower
5-year disease-free survival rate of NPC patients [62]. In
addition, miR-155 expression is upregulated in EBV-positive
NPC tissue samples and is correlated with plasma DNA
copies of LMP1. The expression of miR-155 is also upregu-
lated in the NPC cell lines when transfected with an LMP1-
expressing plasmid. Upregulated miR-155 stimulates NPC
cell proliferation, colony formation, cell migration, and inva-
sion [63].
miR-214 is known to be overexpressed in NPC cell
lines and tissues. miR-214 not only promotes NPC cell
proliferation and invasion in vitro but also accelerates
tumor formation and lung metastasis (Fig. 1). The expres-
sion of miR-214 is upregulated in NPC samples, especial-
ly in metastasis-prone NPC tumor tissues, while the
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lactotransferrin (LTF) expression level is negatively cor-
related with that of miR-214. These suggest that miR-214
targeting is partly responsible for the LTF downregulation
in the NPC specimens [64]. The silencing of miR-214 by
locked-nucleic-acid–anti-miR-214 in NPC cells results in
the enhancement of apoptosis and suppression of in vitro
cell proliferation and in vivo tumor growth in nude mice.
Luciferase reporter assays have been performed to identi-
fy Bim as a direct target of miR-214 [65].
In addition to the above miRNAs, miR-421, miR-10b,
miR-21, miR-30a, miR-93, miR-144, miR-146a, miR-149,
miR-378, and miR-663 are also known to play oncogenic
roles in NPC tumorigenesis (Fig. 1). Overexpression of
miR-421 inhibits the forkhead box protein O4 (FOXO4)
signaling pathway, and it downregulates p21, p27, Bim,
and ligand (FASL) expression by directly targeting the 3′-
UTR of FOXO4 [66]. miR-10b is highly expressed in
EBV–LMP1-positive NPC cells, and its expression is
downregulated by silencing LMP1 or Twist [67]. miR-
10b mimics can promote the mobility and invasion of
NPC cell lines, while miR-10b inhibitors impede this in-
vasion. In addition, the expression of genes related to
migration and invasion, such as E-cadherin, vimentin,
and matrix metalloproteinase-9 (MMP-9), is different in
CNE-2 cells transfected with miR-10b mimics or treated
with miR-10b inhibitors. And miR-10b is found to upreg-
ulate MMP-9, while knockdown of miR-10b significantly
downregulates E-cadherin expression [68]. miR-21 is an
onco-miR, whose levels are elevated in the NPC tissues.
Consequently, cell migration is notably inhibited by the
downregulation of miR-21 in vitro, while miR-21 inhibi-
tors can downregulate B cell CLL/lymphoma 2 (BCL2)
expression. This suggests that BCL2 may be a target gene
for the initiation and development of NPC [69]. The ex-
pression of miRNA-146a in human NPC was found to be
elevated by EBV-associated antigen LMP1 probably
through the activation of the miRNA-146a promoter [70].
A single-nucleotide polymorphism in miRNA-146a is as-
sociated with an increased risk of NPC [71]. miR-378 is
commonly upregulated in both NPC tissues and NPC,
although this is opposite to the reported results in plasma.
Functional studies have shown that the upregulation of
miR-378 dramatically promotes cell proliferation, colony
formation, migration, and invasion in vitro, as well as
tumor growth in vivo. Mechanistic investigations reveal
that miR-378 overexpression can downregulate the expres-
sion of Transducer of ERBB2 (TOB2), a potential tumor
suppressor, while miR-378 silencing can enhance the
TOB2 expression [72]. miR-663 is found to be upregulated
in NPC cells. Inhibition of miR-663 impairs the in vitro
proliferation of NPC cells and the in vivo tumor growth of
xenografts in nude mice. Mechanistically, miR-663 direct-
ly targets p21 (WAF1/CIP1) to promote cellular G1/S
transition, since the inhibitory effects of miR-663 on the
G1/S transition can be rescued by p21 (WAF1/CIP1) si-
lencing [73].
Metastatic miRNAs in NPC
To successfully metastasize, a tumor cell must accomplish
a complex set of processes including invasion, survival,
and arrest in the circulatory system, as well as coloniza-
tion of foreign organs. Despite great advances in the
knowledge of metastasis biology, the molecular mecha-
nisms are not completely understood. Remarkably, a num-
ber of miRNAs exhibit a regulatory role in the metastatic
program. miRNAs can promote or suppress various steps
in the migration and metastasis of cancer cells [74], there-
by affecting key steps such as EMT, migration, and an-
giogenesis (Fig. 1).
NPC exhibits invasive and metastatic features, and approx-
imately 90 % of NPC patients show cervical lymph node
metastasis at the time of initial diagnosis [75]. miR-93 directly
targets transforming growth factor-β receptor II, thereby pro-
moting NPC cell proliferation, invasion, and metastasis [76].
miR-378 dramatically promotes cell colony formation, migra-
tion, and invasion in vitro. miR-378 overexpression and si-
lencing can downregulate or enhance the expression of the
tumor suppressor TOB2, respectively [72]. miR-30a increases
the capability of metastasis and invasion of the NPC tumor
cells, both in vivo and in vitro, by targeting E-cadherin [77].
miR-155 stimulates NPC cell proliferation, colony formation,
cell migration, and invasion by downregulating the expression
of JMJD1A and BACH1 [63]. miR-144 is inversely correlated
with the expression of tumor suppressor gene phosphatase and
tensin homolog (PTEN) in the NPC specimens and cell lines;
consequently, miR-144 suppresses the expression of PTEN to
increase the expression of phosphorylated protein kinase B
(pAkt) and cyclin D1, and promote G(1)-phase transition and
then decreases the expression of E-cadherin to promote mi-
gration and invasion [78]. The expression of miR-149 is
higher in NPC cell lines 5–8 F with high metastasis ability,
and it promotes their mobility and invasion by downregulating
the expression of E-cadherin [79].
Conversely, a few miRNAs serve as metastasis inhibitors;
miR-200a inhibits the growth, migration, and invasion of
C666-1 cells and conversely regulates EMT [39]. miR-9 is
commonly downregulated in NPC [31]. Ectopic expression of
miR-9 dramatically inhibits the proliferative, migratory, and
invasive capacities of NPC cells in vitro and in vivo. The low
plasma level of miR-9 is significantly correlated with in-
creased lymphatic invasion and advanced TNM stage [32].
miR-9 also inhibits cell growth, migration, and invasion by
regulating chemokine (C-X-C motif) receptor 4(CXCR4) ex-
pression [30]. miR-29c inhibits NPC cell migration and
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invasion in vitro and suppresses lung metastases in vivo by
targeting TIAM1 [35].
EBV-encoded miRNA in NPC
The herpes virus EBV is implicated in NPC and other human
malignancies. EBV-encoded miRNAs are the first group of
viral miRNAs to be identified. Although the close association
of NPC with EBV infection has been known for more than
four decades, the exact role of EBV in the pathogenesis of
NPCmalignancy remains unclear. Utilizing the deep sequenc-
ing technology to characterize the EBVmiRNA transcriptome
in clinical NPC tissues, more than 110,000 sequence reads and
44 Epstein–Barr virus encoded microRNA (EBV BART)
were identified. The miRNA sequence analysis revealed that
most of the highly abundant EBV miRNAs share their seed
sequences (2–7 nt) with human miRNAs; it suggests that the
seed sequence content may be an important factor underlying
the differential accumulation of BART miRNAs [80]. NPC
tumors are known to express a number of EBV-encoded
proteins; they also express a large number of virus-encoded
miRNAs, the most abundant of which are encoded from the
BamHI-A region of the viral genome; they are thus called as
BART miRNAs [81]. EBV-miR-BART1 is involved in regu-
lating the metabolism-associated genes in NPC [82]. miR-
BART17 is significantly more abundant in the plasma samples
from NPC patients compared with those from non-NPC sub-
jects [83]. miR-BART3 is abundantly expressed in NPC cells.
The target site of miR-BART3 is located in the 3′-UTR of the
determination of interleukin 4 commitment 1 (DICE1 ) tumor
suppressor transcript, which is usually underexpressed in
EBV-expressing NPC tissues [84]. The plasma levels of
EBV-miR-BART7 are significantly higher in NPC patients
comparedwith those from healthy individuals. The expression
of EBV-miR-BART7 enhances the proliferation, migration,
and invasion of NPC cells in vitro. Furthermore, NPC cells
expressing EBV-miR-BART7 are more resistant to cisplatin
[85]. miR-BART22 is highly expressed in the NPC tissues,
and it may inhibit MAP3K5 expression, thereby reducing the
phosphorylation of mitogen-activated protein kinase pathway
downstream molecular and then inhibit NPC cell apoptosis
and differentiation, and finally prevent the NPC cells from
immune surveillance [86]. miR-BART9 is highly expressed in
the NPC tissues and EBV-positive NPC cells but not in the
normal tissues. Notably, the level of miR-BART9 expression
was higher than that of miR-21 in eight of the nine NPC
tissues examined.
miRNAs as therapeutic targets or tools
Besides influencing practically all the biological processes
including proliferation and apoptosis, miRNAs have great
potential as therapeutic agents. Possibly, the most important
advantage of miRNAs in comparison with conventional ap-
proaches that target single genes is their ability to target
multiple molecules, frequently in the context of a network.
This renders them extremely efficient in regulating distinct
biological processes relevant to normal and malignant cell
biology.
By miRNA plasmid constructed artificially, miRNA can
effectively interfere with NPC cells by downregulating the
expression of VEGF thus inhibiting the growth of tumor
xenografts in vivo. Future application of miRNA in the gene
therapy of NPC might be expected [87]. Forced expression of
miR-125a-5p is known to enhance proliferation, migration,
and invasion of HONE1 cells. NPC patients exhibit signifi-
cantly higher expression level of miR-125a-5p than healthy
controls. miR-125a-5p and curcumin are known to inhibit or
upregulate the expression of tumor protein 53 (TP53), respec-
tively. Taken together, these results indicate that curcumin
exerts inhibitory effects on NPC by inhibiting the expression
of miR-125a-5p and subsequently enhancing the expression
of TP53 [88].
Low expression of miR-29c is positively correlated with
therapeutic resistance in NPC patients; consequently, miR-29c
substantially enhances the sensitivity of NPC cells to IR and
cisplatin treatment by promoting apoptosis. It also represses
the expression of anti-apoptotic factors, Mcl-1 and Bcl-2, in
the NPC tissues and cell lines [36].
Gefitinib is found to inhibit the proliferation of two NPC
cell lines in vitro and in vivo, wherein HK-1 cells are more
sensitive to gefitinib than human nasopharyngeal carcinoma
cell line 1 (HNE-1) cells. In addition, gefitinib treatment
elevates the miR-125a-5p expression in the two cell lines
and the serum of NPC tumor-bearing mice. This phenomenon
is weak in the HNE-1 cells and strong in the HK-1 cells.
Similarly, miR-125a-5p overexpression improves the anti-
proliferative and pro-apoptotic effects of gefitinib on the
NPC cells, while its downregulation abrogates these effects.
MiR-125a-5p is also known to increase p53 protein expres-
sion in HNE-1 cells and decrease Her2 protein expression in
HNE-1 and HK-1 cells [89].
Interestingly, miRNAs are known to influence cellular
responses to specific therapy including radiotherapy.
Radiosensitivity and radiation dose of X-ray can significantly
affect the expression of miR-7 in the NPC cells, indicating that
miR-7 plays an important role in the radioresistance of NPC
cells. Thus, suppressed miR-7 expression may elevate the
radiosensitivity of NPC cells [90]. miR-205, which is elevated
in the radioresistant NPC cell line CNE-2R, is known to
regulate the expression of PTEN, a tumor suppressor.
Introducing miR-205 into CNE-2 cells suppresses PTEN pro-
tein expression following the activation of AKT; it increases
foci formation and reduces post-irradiation apoptosis. On the
other hand, knocking down miR-205 in CNE-2R cells com-
promises the inhibition of PTEN and increases cell apoptosis
Tumor Biol. (2015) 36:69–79 75
[91]. miRNA-324-3p contributes to the radioresistance of
NPC by regulating the wingless-type MMTV integration site
family, member 2B (WNT2B) signaling pathway. Thus, both
miRNA-324-3p and WNT2B are potential biomarkers for
NPC radioresistance [92].
miRNAs as diagnostic tools
The need for clinical biomarkers for early diagnosis of NPC is
extremely urgent; it should be considered that the survival and
prognosis of NPC patients depends on the stages of the tumor
at the time of detection. Some miRNAs that play an important
role or highly express in NPC tumorigenesis may also serve as
diagnostic or prognostic biomarkers of NPC. For example,
most NPC patients with a poor outcome exhibit a high ex-
pression (>median) of miR-548q (70.6 %) and miR-483-5p
(64.7 %) in their tissue samples, suggesting that miR-548q
and miR-483-5p are potential biomarkers of NPC. Combining
the receiver operating characteristic (ROC) analyses of these
two miRNAs, an area under the ROC curve of 0.737 with
67.1 % sensitivity and 68.0 % specificity was obtained, which
demonstrates the preliminary diagnostic value of plasma
miRNAs [93]. The low level of plasma miR-9 is significantly
correlated with increased lymphatic invasion and advanced
TNM stage. Thus, plasma miR-9 could distinguish the
locoregional from the metastatic NPC cases with high sensi-
tivity and specificity. Furthermore, plasma levels of miR-9 are
significantly elevated in post-treatment samples compared
with pre-treatment samples. Thus, plasma miR-9 may serve
as a useful biomarker to predict NPC metastasis and to mon-
itor tumor dynamics [32]. NPC patients with low miR-483-5p
and miR-103 expression have a better 5-year prognosis than
those with a high expression; similarly, patients with a low
concentration of miR-29a and let-7c have poorer prognosis
[94]. Dicer and Drosha mRNA are significantly downregulat-
ed in NPC tissue specimens and cell lines when compared
with controls, and the low expression of the Dicer and Drosha
proteins is significantly correlated with shorter progression-
free survival and overall survival (OS) of NPC patients [95].
Four serum miRNAs including miR-22, miR-572, miR-
638, and miR-1234 were found to be differentially altered in
NPC, and they were used to construct a miRNA signature.
The combination of this miRNA signature and TNM stage
was found to have a better prognostic value than the TNM
stage or miRNA signature alone [96]. The miRNAs were
found to be expressed differentially in the serum of NPC
patients compared with the healthy controls. Based on these,
a diagnosis equation with Ct difference method has been
established to distinguish NPC cases from non-cancerous
controls and validated for high sensitivity and specificity
[97]. A signature of five miRNAs, each significantly associ-
ated with disease-free survival (DFS), was identified in the
training set. A risk score from the signature and patients
classified as high risk or low risk is calculated. Compared
with the patients with low-risk scores, the patients with high
risk scores in the training set have shorter DFS, distant
metastasis-free survival, and OS [98]. Research from the
Wang group indicated differential miRNA expression during
tumor relapse, demonstrating the potential use of miRNAs in
the classification of the repeated recurrence of NPC, beyond
the histological approach [99].
Conclusions
In summary, it is evident that miRNAs not only represent an
additional level of complexity in the molecular portrait of
NPC, contributing to tumor comprehension and subclassifica-
tion, but also represent easily detectable biomarkers to predict
prognosis and response to therapy. It is essential to validate
their potential as biomarkers in different cohorts of samples,
taking into account the evidence that profiling signatures are
probably more statistically significant that single miRNAs in
predicting outcomes. Moreover, even though the available,
up-to-date data are almost exclusively from pre-clinical sam-
ples, miRNAs are promising therapeutic and diagnostic tools
in NPC research.
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